Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atenolol + hydrochlorothiazide is a fixed-dose combination of two antihypertensive agents used primarily for the treatment of high blood pressure (hypertension). Atenolol is a selective beta-1 adrenergic receptor blocker that reduces heart rate and cardiac output, thereby lowering blood pressure. Hydrochlorothiazide is a thiazide diuretic that increases renal excretion of sodium and water, reducing plasma volume and peripheral vascular resistance. The combination provides additive antihypertensive effects by targeting different physiological pathways. This therapy can also be used to reduce the risk of heart attack, manage angina (chest pain), and treat edema associated with various conditions[3][6]. The order in which these drugs are initiated may influence the magnitude of blood pressure reduction during early therapy[2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on atenolol + hydrochlorothiazide.